Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: Results of a pilot study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: Results of a pilot study

Published:2015-01-20 Issue:3 Volume:69 Page:99-102
ISSN:0887-4476
Container-title:Synapse
language:en
Short-container-title:Synapse

Author:

Huot Philippe¹²,Johnston Tom H.¹,Fox Susan H.¹²,Brotchie Jonathan M.¹

Affiliation:

1. Toronto Western Research Institute, University Health Network; Toronto Ontario Canada

2. Division of Neurology, Movement Disorder Clinic; Toronto Western Hospital, University Health Network; Toronto Ontario Canada

Funder

National Institutes of Health

Parkinson Society Canada

Canadian Institutes of Health Research

Merck & Co., Inc.

Teva Pharmaceutical Industries

Atuka Ltd.

Edmond J Safra Philanthropic Foundation

Krembil Foundation

Merck Serono

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience

Reference21 articles.

1. The cardiovascular safety of rosiglitazone;Ajjan;Expert Opin Drug Saf,2008

2. The pharmacokinetics of pioglitazone in patients with impaired renal function;Budde;Br J Clin Pharmacol,2003

3. Nuclear receptors and lipid physiology: opening the X-files;Chawla;Science,2001

4. Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe;Colca;Am J Physiol Endocrinol Metab,2004

5. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation;Dehmer;J Neurochem,2004

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type 2 diabetes mellitus augments Parkinson’s disease risk or the other way around: Facts, challenges and future possibilities;Ageing Research Reviews;2022-11

2. Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing;Neural Regeneration Research;2022

3. Diabetes, insulin and new therapeutic strategies for Parkinson’s disease: Focus on glucagon-like peptide-1 receptor agonists;Frontiers in Neuroendocrinology;2021-07

4. PPARs as Nuclear Receptors for Nutrient and Energy Metabolism;Molecules;2019-07-12

5. Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey;Journal of Pharmacology and Experimental Therapeutics;2018-03-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3